Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Bristol-Myers Squibb Company ROUTE 206 AND PROVINCE LINE ROAD PRINCETON NJ 08543 USA

www.bms.com Employees: 34,100 P: 609-252-4621

Sector:

Medical

Description:

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.

Key Statistics

Overview:

Market Capitalization, $K 95,994,768
Enterprise Value, $K 135,297,760
Shares Outstanding, K 2,035,081
Annual Sales, $ 48,300 M
Annual Net Income, $ -8,948 M
Last Quarter Sales, $ 11,201 M
Last Quarter Net Income, $ 2,456 M
EBIT, $ 13,452 M
EBITDA, $ 23,052 M
60-Month Beta 0.36
% of Insider Shareholders 0.09%
% of Institutional Shareholders 76.41%
Float, K 2,033,250
% Float 99.91%
Short Volume Ratio 0.42

Growth:

1-Year Return 11.88%
3-Year Return -35.34%
5-Year Return -18.46%
5-Year Revenue Growth 84.74%
5-Year Earnings Growth -75.48%
5-Year Dividend Growth 46.34%

Per-Share Information:

Most Recent Earnings 1.80 on 04/24/25
Next Earnings Date 07/31/25 [BMO]
Earnings Per Share ttm 7.34
EPS Growth vs. Prev Qtr 7.78%
EPS Growth vs. Prev Year 140.91%
Annual Dividend Rate, $ 2.46
Annual Dividend Yield 5.22%
Most Recent Dividend 0.620 on 07/03/25
Next Ex-Dividends Date 07/03/25
Dividend Payable Date 08/01/25
Dividend Payout Ratio 32.93%
Most Recent Split 2-1 on 03/01/99

BMY Ratios

Ratio
Price/Earnings ttm 6.33
Price/Earnings forward 7.17
Price/Earnings to Growth 2.39
Return-on-Equity % 87.62%
Return-on-Assets % 15.98%
Profit Margin % -18.53%
Debt/Equity 2.85
Price/Sales 1.96
Price/Cash Flow 7.89
Price/Book 5.42
Book Value/Share 8.57
Interest Coverage -0.10

BMY Dividends

Date Value
07/03/25 $0.6200
04/04/25 $0.6200
01/03/25 $0.6200
10/04/24 $0.6000
07/05/24 $0.6000
04/04/24 $0.6000
01/04/24 $0.6000
10/05/23 $0.5700
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar